skip to Main Content

As our knowledge of liver physiology expands, so too does our understanding of the critical role played by the vascular system in both the development and progression of liver disease. While liver sinusoidal changes are known to affect disease progression, they also have a knock-on effect, disrupting circulation in the rest of the body. The Cirrhosis and Complications track at Digital ILC 2020 will explore the complex relationship between vascular changes and liver cirrhosis, and will highlight the management of portal hypertension.

In its quest to beat liver disease, EASL efforts include devoting a full track to this topic at its events, supporting consortia and collaborations aimed at advancing pertinent research, and having published the EASL Clinical Practice Guidelines on the Management of Decompensated Cirrhosis, which are consulted worldwide.

The Cirrhosis and Complications programme will allow you to learn, share, and interact, due to its engaging structure containing poster tours, abstract sessions, interactive sessions, industry symposia, meet the experts, and wrap up sessions.

Digital ILC 2020 highlights: portal hypertension

What progress is underway in the field of portal hypertension? What are its key developments from research and trials?
To find out how this research field has evolved since ILC 2019, watch this video, “Portal hypertension highlights” from the session Co-chair, Dr Virginia Hernandez-Gea.

Explore the Cirrhosis and Complications track at Digital ILC 2020

In the Cirrhosis and Complications track, leading specialists will provide a detailed overview of how the liver vasculature contributes, and responds, to liver disease. The sessions will provide a detailed overview on topics such as  experimental aspects of cirrhosis, portal hypertension, clinical aspects, antibiotic prophylaxis and treatment in patients with cirrhosis, acute kidney injury in these patients, and complications of cirrhosis and acute-on-chronic liver failure (ACLF).
Discover below all sessions regarding cirrhosis and complications to be held at Digital ILC 2020:

Abstract session: Cirrhosis – Experimental aspects

27 August 2020 15:30 – 17:00

Chairs: Shilpa Chokshi (United Kingdom) & Wim Laleman (Belgium)

Read more

Abstract session: Portal Hypertension

28 August 2020 11:00 – 12:30

Chairs: Alexander Gerbes (Germany) & Virginia Hernandez-Gea (Spain)

Read more

Abstract session: Complications of cirrhosis and ACLF

29 August 2020 11:00 – 12:30

Chairs: Elsa Solà (Spain) & Mauro Bernardi (Italy)

Read more

Meet the Experts: Acute kidney injury in patients with cirrhosis

29 August 2020 09:30 – 10:00

Chairs: Claire Francoz (France) & Pere Ginès (Spain)

Read more

Antibiotic prophylaxis and treatment in patients with cirrhosis

28 August 2020 17:00 – 18:00

Chair: Alastair O’Brien (United Kingdom)

Read more

Should we treat small varices?

29 August 2020 15:30 – 17:00

Chairs: Annalisa Berzigotti (Switzerland), Mattias Mandorfer (Austria)

Read more

Poster tour: Cirrhosis: ACLF and critical illness

27 August 2020 15:00 – 15:30

Chair: Thierry Gustot (Belgium)

Read more

Poster tour: Cirrhosis and its complications: Clinical

28 August 2020 12:30 – 13:00

Chair: Juan Carlos Garcia Pagan (Spain)

Read more

Poster tour: Cirrhosis and its complications: Experimental and pathophysiology

28 August 2020 15:00 – 15:30

Chair: Christian Trautwein, Germany

Read more

Digital ILC 2020 wrap up session – Cirrhosis and portal hypertension

29 August 2020 17:00 – 17:12

Chair: Guadalupe Garcia-Tsao (United States)

Read more

EASL Clinical Practice Guideline – Management of Decompensated Cirrhosis

When the panel of experts nominated by EASL began work to update the Clinical Practice Guidelines on ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS), it became obvious that they should cover all other complications of decompensated cirrhosis.

Within this framework, a formal definition of decompensated cirrhosis was sought. A silent, asymptomatic course characterizes the natural history of cirrhosis. This until increasing portal pressure and worsening liver function produce a clinical phenotype. In the asymptomatic phase of the disease, usually referred to as compensated cirrhosis, patients may have a good quality of life. Also, the disease may progress undetected for several years. The development of overt clinical signs marks the decompensation. The most frequent of which are ascites, bleeding, encephalopathy, and jaundice.

Read the EASL Guideline on the Management of Decompensated Cirrhosis